Victoria Tzouma


Associate Director in Health Economics and Policy

Victoria Tzouma

Victoria Tzouma is an Associate Director in Health Economics and Policy at the Medical Technology Research Group (MTRG) of LSE Health. Having worked in both the pharmaceutical industry and consulting, Victoria’s expertise lies in Health Technology Assessment (HTA), Pricing and Reimbursement, Pharmaceutical Policy and Market Strategy.

Before joining LSE, Victoria worked as a Market Access Manager at Merck Sharp & Dohme (MSD) in Greece and as an HTA & EBM Manager at MSD UK, gaining experience in HTA submissions in the fields of immunology, diabetes and cardiovascular disease. She has also worked as a Consultant at a global health care consultancy in London, focusing on competitive intelligence and strategic consulting for select pharmaceutical and biotechnology clients, on a variety of therapeutic areas such as oncology, haematology and rare diseases.

At MTRG, Victoria provides consulting work to a wide variety of clients, such as the pharmaceutical and biotechnology industry, national governments and international non-governmental organisations. She has done a considerable amount of quantitative and qualitative work on HTA, analysing the impact of HTA on pricing, reimbursement and market access in different health systems and geographies, investigating the criteria that shape HTA recommendations, early access schemes and accelerated regulatory reviews, and analysing the rationale and patterns behind HTA recommendations.

Victoria is also working on a number of other research topics, including the pharmaceutical pricing and reimbursement regulation in the Middle East and Africa region, the impact assessment of indication expansion on analogues in immunology and risk-sharing and managed-entry agreements.

Victoria has been the main researcher at the RareBestPractices FP7 project, investigating the clinical and economic criteria used by EU countries to evaluate orphan drugs, and the influence of HTA and cost-effectiveness on clinical guidelines for rare diseases. She participated in the “Study on impact analysis of policy options for strengthened EU cooperation on HTA”, commissioned by the European Commission, for which she conducted primary research by interviewing a number of pharmaceutical companies to understand their perspective of the possibility of joint HTA in Europe. She has also worked on chronic diseases, such as rheumatoid arthritis, and the translation of research results for chronic diseases into policies and their implementation.

Victoria holds an MSc in Health Economics, Policy and Management from LSE, an MSc in Literary Translation from the University of Strasbourg (France) and a BSc in Journalism and Communication from the Aristotle University of Thessaloniki (Greece). She has an extensive professional background in journalism and communications and she is fluent in French and Greek, and intermediate in Italian.


Expertise: Health Technology Assessment (HTA); pharmaceutical policy; comparative health policy; pharmaceutical regulation; pricing and reimbursement of medical technologies; health outcomes; systematic reviews

LSE Consulting projects: